FindTrial
Sign In

Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01028443
Enrollment
Unknown
Registered
2009-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2009-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Graft Rejection

Brief summary

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Interventions

DRUGArtelose
DRUGSandimmune

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* Penetrating keratoplasty in eyes without vascularization

Exclusion criteria

* History of previous intraocular surgery

Design outcomes

Primary

MeasureTime frame
The rate of rejection after drop sessation3 years

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026